ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality

European Journal of Cancer

Volumn 48, Issue 4, 2012, Pages 538-546

  Bismar, Tarek A ^a,c,d,e   Dolph, Michael ^a   Teng, Liang Hong ^a   Liu, Shuhong ^a   Donnelly, Bryan ^b,e  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c Departments of Oncology   (Canada)

^d TOM BAKER CANCER CENTRE   (Canada)

^e Prostate Cancer Center   (Canada)

Author keywords

Cancer specific mortality; ERG protein expression; Gleason score; Immunohistochemistrty; Tumour volume

Indexed keywords

GONADORELIN AGONIST; TRANSCRIPTION FACTOR ERG;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER MORTALITY; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; GENE REARRANGEMENT; GENETIC ASSOCIATION; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; TUMOR VOLUME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BIOMARKERS, PHARMACOLOGICAL; CAUSE OF DEATH; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TRANS-ACTIVATORS;

EID: 84862776695     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.01.001     Document Type: Article

References (35)

1. S.A. Tomlins, D.R. Rhodes, and S. Perner Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 5748 2005 644 648 (Pubitemid 41528150)
2. M.J. Soller, M. Isaksson, and P. Elfving Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer Genes Chromosom Cancer 45 7 2006 717 719 (Pubitemid 43727158)
3. S.A. Tomlins, R. Mehra, and D.R. Rhodes TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer Cancer Res 66 7 2006 3396 3400
4. B.E. Helgeson, S.A. Tomlins, and N. Shah Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer Cancer Res 68 1 2008 73 80 (Pubitemid 351380107)
5. K.G. Hermans, H.A. van der Korput, and R. van Marion Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer Cancer Res 68 18 2008 7541 7549
6. S. Perner, F. Demichelis, and R. Beroukhim TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer Cancer Res 66 17 2006 8337 8341 (Pubitemid 44449140)
7. W. Liu, C.M. Ewing, and B.L. Chang Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers Genes Chromosom Cancer 46 11 2007 972 980 (Pubitemid 47502837)
8. L.M. FitzGerald, I. Agalliu, and K. Johnson BMC Cancer 8 2008 230
9. D. Hessels, F.P. Smit, and G.W. Verhaegh Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer Clin Cancer Res 13 17 2007 5103 5108 (Pubitemid 47502077)
10. F. Demichelis, K. Fall, and S. Perner TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort Oncogene 26 31 2007 4596 4599 (Pubitemid 47037039)
11. S. Liu, M. Yoshimoto, and K. Trpkov Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone Cancer Biol Ther 11 6 2011 562 566
12. T.L. Lotan, A. Toubaji, and R. Albadine TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas Mod Pathol 22 3 2009 359 365
13. AH. Reid, G. Attard, and L. Ambroisine Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer Br J Cancer 102 4 2010 678 684
14. R.K. Nam, L. Sugar, and W. Yang Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer Br J Cancer 97 12 2007 1690 1695 (Pubitemid 350249347)
15. O.R. Saramaki, A.E. Harjula, and P.M. Martikainen TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis Clin Cancer Res 14 11 2008 3395 3400
16. A.D. Darnel, C.J. Lafargue, R.T. Vollmer, J. Corcos, and T.A. Bismar TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort Cancer Biol Ther 8 2 2009 125 130
17. G.J. van Leenders, J.L. Boormans, and C.J. Vissers Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice Mod Pathol 24 8 2011 1128 1138
18. B. Furusato, S.H. Tan, and D. Young ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification Prostate Cancer Prostatic Dis 13 3 2010 228 237
19. T.L. Lotan, N.S. Gupta, and W. Wang ERG gene rearrangements are common in prostatic small cell carcinomas Mod Pathol 24 6 2011 820 828
20. M. Miettinen, Z.F. Wang, and A. Paetau ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma Am J Surg Pathol 35 3 2011 432 441
21. K. Park, S.A. Tomlins, and K.M. Mudaliar Antibody-based detection of ERG rearrangement-positive prostate cancer Neoplasia 12 7 2010 590 598
22. A. Chaux, R. Albadine, and A. Toubaji Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas Am J Surg Pathol 35 7 2011 1014 1020
23. J.I. Epstein, W.C. Allsbrook Jr., M.B. Amin, and L.L. Egevad The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma Am J Surg Pathol 29 9 2005 1228 1242 (Pubitemid 41232997)
24. Hoogland AM, Jenster G, van Weerden WM, et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol 2011, Nov 11 (Epub ahead of print).
25. Y. Zong, L. Xin, and A.S. Goldstein ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells Proc Natl Acad Sci USA 106 30 2009 12465 12470
26. Bismar TA, Yoshimoto, M, Duan Q, et al. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration resistant prostate cancer. histopathology 2012, Jan 19 (Epub ahead of print).
27. O. Leshem, S. Madar, and I. Kogan-Sakin TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model PLoS ONE 6 7 2011 e21650
28. O. Yaskiv, X. Zhang, and K. Simmerman The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies Am J Surg Pathol 35 7 2011 1062 1068
29. S.M. Falzarano, M. Zhou, and P. Carver ERG gene rearrangement status in prostate cancer detected by immunohistochemistry Virchows Arch 459 4 2011 441 447
30. S. Minner, M. Enodien, and H. Sirma ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy Clin Cancer Res 17 18 2011 5878 5888
31. M. Braun, V.J. Scheble, and R. Menon Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer Histopathology 58 7 2011 1028 1036
32. M.A. Rubin, C.A. Maher, and A.M. Chinnaiyan Common gene rearrangements in prostate cancer J Clin Oncol 29 27 2011 3659 3668
33. S.A. Tomlins, A. Bjartell, and A.M. Chinnaiyan ETS gene fusions in prostate cancer: from discovery to daily clinical practice Eur Urol 56 2 2009 275 286
34. A. Toubaji, R. Albadine, and A.K. Meeker Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas Mod Pathol 24 11 2011 1511 1520
35. G. Attard, A.H. Reid, D. Olmos, and J.S. de Bono Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven Cancer Res 69 12 2009 4937 4940